| |DECEMBER 20249INDIA'S DIALYSIS MARKET FACES HIGH COSTS WITH 3PERCENT APAC SHAREINNOVATION & BIOPHARMA RESEARCH FUEL GROWTH IN SPECIALTY PHARMA MARKETThe dialysis machines sector in India makes up around 3 Percent of the Asia Pacific market, with the majority of machines being imported, leading to increased expenses. GlobalData reported that the market is expected to reach $14 million by 2033 due to the high occurrence and impact of chronic kidney diseases.Nephro Care India Limited is collaborating with the National Institute of Technology, Silchar to create a prototype of an AI-enabled, remotely monitored machine, with the goal of cutting costs by approximately 75 Percent to about $2,368.5 (INR 200,000), a significant development.At the same time, Shreya Jain, the medical devices analyst at GlobalData, noted that although haemodialysis machines are more readily available, obstacles in access, cost, and care standards persist."Local production support and infrastructure could help manufacturers tailor machines to India's needs and reduce maintenance expenses, making dialysis more affordable and accessible," the analyst said.A large group of patients with end-stage renal disease (ESRD), a major global health issue, need dialysis to filter toxins from their kidneys and maintain a stable life.The rising prevalence of end-stage renal disease is primarily caused by the growing number of chronic conditions like type 2 diabetes and hypertension. If left untreated, these conditions will result in gradual harm to the kidneys, ultimately resulting in End-Stage Renal Disease (ESRD) if medications are not utilized. Aging individuals are at a higher risk for decreased kidney function and associated complications, making it one of the major factors to consider. POContinuous innovation and biopharmaceutical research are driving growth in the specialty pharmaceutical market. The industry's dedication to creating innovative treatment choices plays a crucial role in achieving better disease targeting with fewer side effects, particularly beneficial for conditions such as autoimmune diseases and cancers.The pharmaceutical manufacturing industry is being transformed by digitalization and automation, especially with the introduction of Pharma 4.0 technologies. These advancements are vital for improving production efficiency and flexibility, allowing for real-time release testing and the use of digital twins to enhance manufacturing processes. These technological changes greatly enhance efficiency and guarantee adherence to industry regulations.Moreover, the changing regulatory policies are significantly impacting the specialty pharmaceutical market. Shifts in drug pricing and reimbursement structures, focusing more on value-based and transparent pricing methods, significantly influence market dynamics. Regulatory changes play a key role in establishing pricing and reimbursement rates for specialty medications and influencing broader market patterns.Recent approvals from regulators continue to emphasize the quick growth of the sector. Some notable approvals are Pfizer Inc. and BioNTech SE's COVID-19 booster for Omicron BA.4/BA.5, AbbVie Inc.'s Rinvoq for ulcerative colitis, and Amgen Inc.'s Enbrel for non-radiographic axial spondyloarthritis. These endorsements display the continuing creativity in the specialized pharmaceutical sector, highlighting its crucial contribution to improving worldwide healthcare standards and treatment choices. PO
< Page 8 | Page 10 >